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 In high-income countries, such as the UK, mental health problems are among the most 
prevalent medical conditions. These conditions can have a devastating impact on the 
population; for example, accidental poisoning from opioid addiction is one of the leading 
causes of death among younger adults in the United States (US). While the UK has not faced 
a similar opioid epidemic, addiction and other psychiatric disorders still contribute to our 
public health burden (Mordecai et al., 2018).  
Despite the pressing need for new and more effective treatments, many pharmaceutical 
companies have moved away from researching psychiatric medicines. A string of high-profile 
failed phase III trials may further discourage investment in psychiatric drug development. 
There are effective alternatives to psychiatric medications — talking therapies, for example 
— but their outcomes are generally no better than treatment with drugs. And around half of 
patients with anxiety and depression fail to recover by the end of treatment. 
The basic neurobiological and psychological processes that underlie psychiatric disorders are 
only beginning to be uncovered. The disorders are seen as a ‘moving target’: many distinct 
symptoms manifest differently in different people.  
There has been historical (and continued) over-reliance on pathognomonic (characteristic) 
diagnostic frameworks, such as the American Psychiatric Association’s Diagnostic and 
Statistical Manual of Mental Disorders. A recent drive by the National Institute of Mental 
Health in the United States — the Research Domain Criteria initiative — has encouraged a 
better understanding of the fundamental psychological and biological processes that are 
common across psychiatric disorders. 
When psychiatric symptoms are viewed ‘transdiagnostically’ (ie. by focusing on symptoms 
rather than on a diagnosis), treatment of a wide array of distinct symptoms can become more 
manageable because only a small set of disordered processes must be targeted. With a focus 
on common processes, the overlapping causes and maintaining factors of distinct disorders 
also become clearer. 
Psychiatric disorders often occur concurrently, so reversing a limited number of disordered 
psychological processes may have an impact on a range of co-morbid problems. Among these 
processes, a dysregulation of learning and memory seems to be critical in the onset and 
maintenance of anxiety disorders and addiction.  
At first sight, these disorders do not have much in common. Addiction, for example, involves 
a loss of control over drug taking, whereas people with anxiety disorders often have 
difficulties associated with ‘over-control’ (of feelings and behaviours). Yet, there are indeed 
similarities in the psychological processes involved in both disorder types, especially in 
relation to the role of learning and memory. Consider, for example, patients with severe 
alcohol problems. Obtaining and consuming alcohol is an overriding priority for them, and 
these behaviours often occur at the expense of other important activities. Thoughts about 
alcohol and drinking come to mind automatically, evoked by reminders of alcohol-use in the 
environment. For example, the smell or sight of alcohol readily triggers intense craving, 
followed by excessive drinking, despite attempts to resist. In alcohol addiction, these 
behavioural ‘routines’ are so well-rehearsed and stereotyped that they can be triggered 
relatively automatically, promoting drinking without deliberation (‘mindless’ drinking). In 
one way or another, all of these phenomena (intrusive thoughts about alcohol; craving; 
drinking without thinking) reflect abnormal learned responses stored in ‘maladaptive memory 
traces.’  
Similarly, in phobias and posttraumatic stress disorder (PTSD), physiological, behavioural 
and cognitive responses are triggered when the individual is confronted by the feared 
situation or object, reflecting learned associations between a feared stimulus and a fear 
response. Moreover, visual memories, in the form of distressing mental images of frightening 
situations or phobic objects come to mind unintentionally (e.g. in the form of ‘flashbacks’). 
Again then, disordered learning and memory play a core role in fear-related disorders.   
Learning is the process of forming new associations between occurrences in the outside 
world and events inside the body. Usually these co-occurrences need to happen repeatedly to 
cement the associations into long-term memory. For example, repeated drug-taking in a 
particular environment, leads to the formation of a ‘drug memory,’ which is automatically 
activated the next time the person is in that environment, resulting in craving and reflexive 
drug-seeking and consumption. But repetition isn’t always necessary for strong learning to 
occur. Some events are so salient or stressful that a single experience can leave an indelible 
mark on the mind. For example, traumatic memories are formed after a single life-threatening 
event (like a car accident), and activation of the traumatic memory (e.g. by the sound of a 
speeding car) results in fear, and the urge to escape (resulting in, for example, avoidance of 
busy roads).  
At the cellular level, learning involves the formation and sculpting of synaptic connections 
between neurons in key areas of the brain (like the amygdala and hippocampus), whereas 
‘remembering’ involves reactivation of the networks of neural connections formed during 
learning. Much contemporary research in neuroscience has focused on the cellular and 
molecular mechanisms underlying these neural processes. Behavioural neuroscientists often 
use rodent models of psychiatric disorders to tease apart the role of specific brain circuits in 
behavioural dysregulation. They employ a variety of techniques, including localised 
pharmacological treatments directed at specific brain regions, to decipher the role of 
particular neurotransmitter systems in those regions. These studies have shown that abnormal 
neurotransmission is associated with dysregulation in fear and reward learning circuitry in 
rodent models of anxiety and addiction respectively. Modern neuroimaging techniques show 
similar neural changes in the equivalent brain structures in people with anxiety and addiction.  
In our research at the Clinical Psychopharmacology Unit at UCL, we use insights from 
laboratory studies in animals to study how learning and memory processes go awry, and to 
understand how these processes might be ameliorated in humans. We do this by, for example, 
training participants to be afraid of simple auditory and visual stimuli by repeatedly pairing 
these with uncomfortable electric shocks (‘Pavlovian conditioning’). After a number of 
repetitions, participants begin to respond fearfully to the harmless auditory/visual stimuli, a 
simulation of the processes that occur naturally in specific phobias. In other experiments, we 
show participants disturbing film scenes, causing them to remember these scenes 
involuntarily over the next several days (equivalent to flashbacks in PTSD). By simulating 
phobic and traumatic reactions, we have been able to ask whether the symptoms of phobias 
and PTSD can be reversed using drugs that interfere with the neural processes involved in 
laying down fearful or traumatic memories. If so, these drugs could be developed to prevent 
or treat these disorders. 
Drugs like propranolol and hydrocortisone, which have well known anti-hypertensive and 
anti-inflammatory properties respectively, can also impair certain types of learning and 
memory. This might initially seem surprising, since acute cognitive impairment is not a 
commonly reported side effect of these drugs, at least in people without systemic diseases. In 
fact, their memory impairing effects only seem to occur under specific and time-limited 
circumstances. In particular, amnesia for certain types of (emotional) information is evident if 
propranolol or hydrocortisone are administered within a brief window of opportunity, when 
the memory has not yet fully stabilised or ‘consolidated’. Memory consolidation - a process 
that unfolds over several hours after initial learning - is driven by intense synaptic protein 
synthesis and post-translational modification, leading to the remodelling of synapses and a 
‘cementing’ of memories in long-term storage. β-adrenoceptor and corticosteroid antagonists 
are thought to prevent these structural and functional changes at synapses in brain regions 
involved in processing emotional information, and as a result, these drugs prevent the 
formation of long-term emotional memories.  
These discoveries were originally made in non-human animals using direct infusions of 
propranolol and corticosteroids into brain regions critical for emotional learning and memory 
(e.g. the amygdala and hippocampus; McGaugh, 2004). However, oral propranolol and 
hydrocortisone, which are lipophilic and readily cross the blood-brain barrier, can also impair 
emotional memory formation in humans. Early studies investigated memory for simple 
stimuli (lists of words and pictures), and showed that the effects of these drugs were quite 
circumscribed: they appeared to strip away the negative emotions associated recalling 
unpleasant events (e.g. Cahill et al, 1994). These basic psychopharmacological experiments 
provided a rationale for testing the effects of propranolol and hydrocortisone in clinical trials 
targeting much more distressing memories, like those seen in PTSD. The results have been 
promising (especially with hydrocortisone; Sijbrandij et al, 2015). More importantly perhaps, 
these trials are an excellent example of how neuroscience-driven research can lead to a 
repurposing of drugs for novel applications in psychiatry. Such re-purposing can overcome 
the enormous financial barriers and high failure rates associated with bringing new 
compounds to market. 
In our own experiments, we have tested whether other drugs might also interfere with 
pathological learning and memory in PTSD and addictions, focusing primarily on 
glutamatergic antagonists. Since glutamatergic signalling, particularly at NMDA receptors, is 
fundamental to synaptic plasticity (and therefore memory consolidation), its disruption may 
provide an additional route to preventing the long-term storage of fear- or addiction-related 
memories. We showed, for example, that compared to medical air, the anaesthetic gas and 
NMDA antagonist, nitrous oxide, can speed up the reduction in distressing intrusive 
memories in the days after a simulated traumatic event (Das et al, 2016). These findings 
provided preliminary evidence that nitrous oxide, a widely used drug with an excellent safety 
profile, might also be useful in preventing the onset of PTSD.  Our ongoing research with 
nitrous oxide also suggests that it may have similar effects in weakening addiction-related 
memories.    
In particular, our experiments on addiction-related memories assess whether it is possible to 
interfere with the pre-existing memories that drive heavy drinking. In these studies, 
participants’ associations between alcohol and reward are already well-established (they are 
formed through repeatedly pairing alcohol-related stimuli or ‘cues’ with the intoxicating and 
rewarding effects of alcohol in participants’ natural environments). These associations are 
likely to be very strong, as they are formed over years of drinking. A key question remains 
whether it is possible to interfere with pre-existing memories that are strongly (and naturally) 
‘trained’.  To address this, our translational approach is currently focussing on a very 
promising memory plasticity process called memory reconsolidation (Kamboj & Das, 2017). 
This process involves the ‘updating’ of consolidated memories, and is triggered when these 
memories are retrieved in the presence of new, relevant information. This updating requires a 
brief period of memory ‘destabilisation’ which provides an additional window of opportunity 
(similar to that afforded when the memory is initially being consolidated) to use the 
aforementioned amnestic drugs to weaken pre-existing memories in addiction or anxiety 
disorders. Our preliminary findings with glutamatergic antagonists, suggest that this is a 
promising approach in heavy drinkers. 
We believe these memory-weakening approaches have enormous potential in psychiatric 
treatment. However, they are only concerned with processes occurring within the individual 
and we should not lose sight of the role that social factors play in psychiatric disorders. The 
opioid crisis in the US challenges our assumptions about what it means to be ‘an addict’, as 
individuals across the age and socioeconomic spectrum are affected by opioid addiction. Here 
in the UK, researchers have found a link between socioeconomic deprivation and increased 
rates of opioid prescription (Mordecai et al., 2018). This highlights that social and economic 
distress play an extremely important role in the development and maintenance of psychiatric 
disorder. Any isolated intervention approach, for example, one that only targets abnormal 
psychological processes within the individual, while ignoring critical environmental 
contributors to distress, is unlikely to be effective in the long term. Once we’ve established 
the therapeutic potential of memory interfering pharmacological strategies, the next step will 
be to integrate these into holistic treatments that provide comprehensive support to people 
with anxiety and substance use disorders.   
References 
Cahill, L, Prins B, Weber M, & McGaugh JL (1994) Beta-adrenergic activation and memory 
for emotional events. Nature, 371(6499), 702-704 
Das, R. K., Tamman, A., Nikolova, V., Freeman, T. P., Bisby, J. A., Lazzarino, A. I., & 
Kamboj, S. K. (2016). Nitrous oxide speeds the reduction of distressing intrusive memories 
in an experimental model of psychological trauma. Psychological Medicine, 46(8), 1749-
1759. 
 
Kamboj SK, Das RK (2017). Behavioral and Pharmacological Strategies for Weakening 
Maladaptive Reward Memories: A New Approach to Treating a Core Disease Mechanism in 
Tobacco Use Disorder. JAMA Psychiatry, 74(3):209-211. 
McGaugh, J. L. (2004). The amygdala modulates the consolidation of memories of 
emotionally arousing experiences. Annual Review of Neuroscience, 27, 1-28. 
 
Mordecai, L., Reynolds, C., Donaldson, L. J., & de C Williams, A. C. (2018). Patterns of 
regional variation of opioid prescribing in primary care in England: a retrospective 
observational study. British Journal of General Practice, bjgp18X695057. 
 
Sijbrandij, M., Kleiboer, A., Bisson, J. I., Barbui, C., & Cuijpers, P. (2015). Pharmacological 
prevention of post-traumatic stress disorder and acute stress disorder: a systematic review and 
meta-analysis. The Lancet Psychiatry, 2(5), 413-421. 
 
